Cipla to acquire Inzpera Healthsciences for Rs. 110.65 Cr
The transaction is expected to be completed within one month from the signing of the definitive agreements.
The transaction is expected to be completed within one month from the signing of the definitive agreements.
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
PET sheets are widely recognised for their superior clarity, strength, and barrier properties
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
Subscribe To Our Newsletter & Stay Updated